$ZURA
Zura Bio Ltd

2024 Q2 Form 10-Q Financial Statement

#000141057824001371 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.220M
YoY Change 9.51%
% of Gross Profit
Research & Development $5.539M
YoY Change -80.38%
% of Gross Profit
Depreciation & Amortization $1.000K
YoY Change
% of Gross Profit
Operating Expenses $11.76M
YoY Change -65.32%
Operating Profit -$11.76M
YoY Change -65.32%
Interest Expense $1.428M
YoY Change -369.43%
% of Operating Profit
Other Income/Expense, Net $1.430M
YoY Change -1291.67%
Pretax Income -$10.33M
YoY Change -69.64%
Income Tax
% Of Pretax Income
Net Earnings -$10.33M
YoY Change -69.62%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$0.17
COMMON SHARES
Basic Shares Outstanding 43.59M
Diluted Shares Outstanding 74.95M

Balance Sheet

Concept 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $188.4M
YoY Change 67.06%
Cash & Equivalents $188.4M
Short-Term Investments
Other Short-Term Assets $1.032M
YoY Change 106.4%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $189.5M
YoY Change 67.19%
LONG-TERM ASSETS
Property, Plant & Equipment $25.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $25.00K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $189.5M
Total Long-Term Assets $25.00K
Total Assets $189.5M
YoY Change 67.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $990.0K
YoY Change -85.96%
Accrued Expenses $14.08M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.07M
YoY Change -24.41%
LONG-TERM LIABILITIES
Long-Term Debt $2.364M
YoY Change 12.57%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.364M
YoY Change 12.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.07M
Total Long-Term Liabilities $2.364M
Total Liabilities $17.44M
YoY Change -20.77%
SHAREHOLDERS EQUITY
Retained Earnings -$121.6M
YoY Change 40.06%
Common Stock $6.000K
YoY Change 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $156.5M
YoY Change
Total Liabilities & Shareholders Equity $189.5M
YoY Change 67.21%

Cashflow Statement

Concept 2024 Q2
OPERATING ACTIVITIES
Net Income -$10.33M
YoY Change -69.62%
Depreciation, Depletion And Amortization $1.000K
YoY Change
Cash From Operating Activities -$6.617M
YoY Change 27.99%
INVESTING ACTIVITIES
Capital Expenditures $10.00K
YoY Change -99.83%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K
YoY Change -99.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 105.3M
YoY Change 31.95%
NET CHANGE
Cash From Operating Activities -6.617M
Cash From Investing Activities -10.00K
Cash From Financing Activities 105.3M
Net Change In Cash 98.63M
YoY Change 43.25%
FREE CASH FLOW
Cash From Operating Activities -$6.617M
Capital Expenditures $10.00K
Free Cash Flow -$6.627M
YoY Change -39.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
zura Transfers Between Level2 And Level3
TransfersBetweenLevel2AndLevel3
0
CY2024Q2 zura Transfers Between Level2 And Level3
TransfersBetweenLevel2AndLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
dei Entity Central Index Key
EntityCentralIndexKey
0001855644
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63683806
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43593678
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40598
dei Entity Registrant Name
EntityRegistrantName
ZURA BIO LIMITED
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1725736
dei Entity Address Address Line1
EntityAddressAddressLine1
1489 W. Warm Springs Rd. #110
dei Entity Address City Or Town
EntityAddressCityOrTown
Henderson
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89014
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
757-6133
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 us-gaap Cash
Cash
188443000
CY2023Q4 us-gaap Cash
Cash
99806000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1032000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1037000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
189475000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
100843000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25000
CY2024Q2 us-gaap Assets
Assets
189500000
CY2023Q4 us-gaap Assets
Assets
100843000
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15073000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15073000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20302000
CY2024Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
2364000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
990000
CY2024Q2 us-gaap Liabilities
Liabilities
17437000
CY2023Q4 us-gaap Liabilities
Liabilities
21292000
CY2024Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
14000000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18680000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63683806
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43593678
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
278086000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162820000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121570000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103494000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
156522000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
59330000
CY2024Q2 us-gaap Minority Interest
MinorityInterest
1541000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
1541000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
158063000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189500000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100843000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5539000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28230000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9132000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33114000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6220000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5675000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11006000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8510000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
11759000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
33905000
us-gaap Operating Expenses
OperatingExpenses
20138000
us-gaap Operating Expenses
OperatingExpenses
41624000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11759000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33905000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20138000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41624000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2196000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3411000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2023Q2 us-gaap Investment Income Dividend
InvestmentIncomeDividend
405000
us-gaap Investment Income Dividend
InvestmentIncomeDividend
405000
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
768000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
532000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1374000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
355000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1430000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-120000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2062000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2196000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10329000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34025000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18076000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43820000
CY2024Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-10329000
CY2023Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-34025000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18076000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-43820000
us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-203000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10329000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34025000
us-gaap Net Income Loss
NetIncomeLoss
-18076000
us-gaap Net Income Loss
NetIncomeLoss
-43617000
CY2024Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2337000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2337000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
CY2023Q2 zura Deemed Dividend To Redeemable Noncontrolling Interest
DeemedDividendToRedeemableNoncontrollingInterest
10875000
zura Deemed Dividend To Redeemable Noncontrolling Interest
DeemedDividendToRedeemableNoncontrollingInterest
10875000
zura Temporary Equity Redemption Value To Carrying Value Adjustment
TemporaryEquityRedemptionValueToCarryingValueAdjustment
7017000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12666000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-44900000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13396000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54695000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74947369
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74947369
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34303125
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34303125
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60930956
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60930956
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19012464
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19012464
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5335000
zura Temporary Equity Redemption Value To Carrying Value Adjustment
TemporaryEquityRedemptionValueToCarryingValueAdjustment
7017000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2337000
us-gaap Net Income Loss
NetIncomeLoss
-18076000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
158063000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32056000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
14686000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4000000.0
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
48351000
zura Stock Issued During Period Value Research And Development License Consideration Liability
StockIssuedDuringPeriodValueResearchAndDevelopmentLicenseConsiderationLiability
4488000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2001000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8088000
us-gaap Net Income Loss
NetIncomeLoss
-43617000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
zura Value Of Issued Call Right
ValueOfIssuedCallRight
1541000
zura Adjustment Of Deemed Dividend To Redeemable Noncontrolling Interest
AdjustmentOfDeemedDividendToRedeemableNoncontrollingInterest
10875000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70448000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
62550000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2926000
CY2024Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2337000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10329000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
158063000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
27855000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7908000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34025000
CY2023Q2 zura Value Of Issued Call Right
ValueOfIssuedCallRight
1541000
CY2023Q2 zura Adjustment Of Deemed Dividend To Redeemable Noncontrolling Interest
AdjustmentOfDeemedDividendToRedeemableNoncontrollingInterest
10875000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70448000
CY2024Q2 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
us-gaap Profit Loss
ProfitLoss
-18076000
us-gaap Profit Loss
ProfitLoss
-43820000
zura Research And Development Expense On Acquired License
ResearchAndDevelopmentExpenseOnAcquiredLicense
27381000
zura Anti Dilution Share Issuance Compensation
AntiDilutionShareIssuanceCompensation
2186000
us-gaap Share Based Compensation
ShareBasedCompensation
5335000
us-gaap Share Based Compensation
ShareBasedCompensation
2498000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
zura Increase Decrease In Research And Development License Consideration Liability
IncreaseDecreaseInResearchAndDevelopmentLicenseConsiderationLiability
1854000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1374000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
355000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
25000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
321000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-213000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-813000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11599000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8430000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5000000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5750000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5017000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5750000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56683000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000000
zura Payment Of Deferred Transaction Costs
PaymentOfDeferredTransactionCosts
1184000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
105253000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
125415000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
88637000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
111235000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99806000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1567000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188443000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112802000
zura Conversion Of Series One Convertible Preferred Shares For Ordinary Shares
ConversionOfSeriesOneConvertiblePreferredSharesForOrdinaryShares
14686000
zura Accrued License Consideration
AccruedLicenseConsideration
12250000
zura Adjustment Of Deemed Dividend To Redeemable Noncontrolling Interest
AdjustmentOfDeemedDividendToRedeemableNoncontrollingInterest
10875000
zura Issuance Of Shares For Consideration License
IssuanceOfSharesForConsiderationLicense
7840000
zura Temporary Equity Redemption Value To Carrying Value Adjustment Non Cash Activities
TemporaryEquityRedemptionValueToCarryingValueAdjustmentNonCashActivities
7017000
zura Share Based Equity Issuance Costs
ShareBasedEquityIssuanceCosts
5590000
zura Settlement Of Research And Development License Consideration Liability
SettlementOfResearchAndDevelopmentLicenseConsiderationLiability
4488000
zura Transaction Costs Include In Accounts Payable
TransactionCostsIncludeInAccountsPayable
4122000
zura Reclassification Of Deferred Transaction Costs To Additional Paid In Capital
ReclassificationOfDeferredTransactionCostsToAdditionalPaidInCapital
4015000
zura Assumption Of Public And Private Placement Warrants In Connection With Business Combination
AssumptionOfPublicAndPrivatePlacementWarrantsInConnectionWithBusinessCombination
3715000
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2337000
zura Reclassification Of Public Warrant Liability To Equity
ReclassificationOfPublicWarrantLiabilityToEquity
2001000
zura Issuance Of Call Right To Noncontrolling Interest
IssuanceOfCallRightToNoncontrollingInterest
1541000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26292385
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21889478
zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
CY2024Q2 zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
zura Gain Or Loss On Remeasurement Of Research And Development License Consideration Liability
GainOrLossOnRemeasurementOfResearchAndDevelopmentLicenseConsiderationLiability
1900000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
990000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1374000
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2364000
CY2024Q2 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7149000
CY2023Q4 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6091000
CY2024Q2 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
5000000
CY2023Q4 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
10000000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
990000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2749000
CY2024Q2 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
837000
CY2023Q4 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
1201000
CY2024Q2 zura Accrued Severance Costs Current
AccruedSeveranceCostsCurrent
696000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
401000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
261000
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15073000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2023Q1 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
267939
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
50099022
CY2024Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
zura Number Of Warrants Exercised Or Redeemed
NumberOfWarrantsExercisedOrRedeemed
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2926000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2319000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5335000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4685000
CY2024Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
14000000.0
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18700000
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001371-index-headers.html Edgar Link pending
0001410578-24-001371-index.html Edgar Link pending
0001410578-24-001371.txt Edgar Link pending
0001410578-24-001371-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zura-20240630.xsd Edgar Link pending
zura-20240630x10q.htm Edgar Link pending
zura-20240630xex31d1.htm Edgar Link pending
zura-20240630xex31d2.htm Edgar Link pending
zura-20240630xex32d1.htm Edgar Link pending
zura-20240630xex32d2.htm Edgar Link pending
zura-20240630_cal.xml Edgar Link unprocessable
zura-20240630_lab.xml Edgar Link unprocessable
zura-20240630_def.xml Edgar Link unprocessable
zura-20240630x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
zura-20240630_pre.xml Edgar Link unprocessable